Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been assigned an average recommendation of “Hold” from the five analysts that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $13.75.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. The trade was a 1.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by company insiders.

Institutional Trading of Theravance Biopharma

Several hedge funds have recently bought and sold shares of the company. Barclays PLC grew its position in Theravance Biopharma by 279.9% in the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after purchasing an additional 48,316 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Theravance Biopharma in the 3rd quarter worth approximately $251,000. XTX Topco Ltd increased its position in Theravance Biopharma by 34.5% in the 3rd quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 5,243 shares during the period. Jane Street Group LLC raised its stake in Theravance Biopharma by 1.1% during the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after acquiring an additional 1,640 shares in the last quarter. Finally, PDT Partners LLC boosted its position in Theravance Biopharma by 31.2% during the 3rd quarter. PDT Partners LLC now owns 87,177 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 20,738 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $9.88 on Monday. The firm has a market cap of $485.80 million, a P/E ratio of -9.74 and a beta of 0.23. Theravance Biopharma has a 1 year low of $7.44 and a 1 year high of $11.71. The firm’s 50 day moving average price is $9.01 and its 200 day moving average price is $8.75.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $16.87 million for the quarter, compared to analyst estimates of $16.11 million. During the same quarter last year, the business earned ($0.17) EPS. As a group, equities analysts predict that Theravance Biopharma will post -1.09 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.